1347008-73-4

Basic information

• Product Name: 1-(2-chloro-4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)-3-(4-methyl-3-(trifluoromethyl)phenyl)urea
• Synonyms: 1-(2-chloro-4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)-3-(4-methyl-3-(trifluoromethyl)phenyl)urea
• CAS NO: 1347008-73-4
• Molecular Weight: 555.867
• Mol File: 1347008-73-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(2-chloro-4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)-3-(4-methyl-3-(trifluoromethyl)phenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloro-4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)-3-(4-methyl-3-(trifluoromethyl)phenyl)urea(1347008-73-4)
• EPA Substance Registry System: 1-(2-chloro-4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)-3-(4-methyl-3-(trifluoromethyl)phenyl)urea(1347008-73-4)

Safety Data

• Hazardous Substances Data: 1347008-73-4(Hazardous Substances Data)

Upstream product

• 1347008-91-6 C₁₇H₁₂ClF₃N₄O₂ 
• 1347008-89-2 C₁₄H₁₀ClN₃O₂ 
• 51903-64-1 4-isocyanato-1-methyl-2-(trifluoromethyl)benzene 
• 1347008-93-8 C₁₅H₁₀ClF₃N₄O 
• 5470-22-4 4-chloropicolinic acid 
• 99586-65-9 4-chloropicolinamide 
• 19235-89-3 4-chloro-pyridine-2-carbonitrile 

Relevant articles and documents

Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors

A series of novel bis-aryl ureas containing trifluoromethyl imidazolyl group targeting Raf kinase were designed and synthesized based on the lead compound of Sorafenib. All the prepared compounds were evaluated for their in vitro antiproliferative activities against three human cancer cell lines including MDA-MB-231 (breast), BGC-823 (gastric), and SMMC-7721 (liver). Several compounds from the series exhibited excellent antitumor activities against all three tested cancer lines. Further their inhibitory activities against Raf kinase were investigated, and three compounds (11c, 11d, and 11p) demonstrated better activities than contrast drug Sorafenib. Especially compound 11c was found to be a potent and selective Raf kinase inhibitor and could be considered as a candidate compound for further development.